VeraDermics (MANE) news
Recent news
VeraDermics (MANE) shares rose 12.44% in intraday trading after the release of positive clinical trial results for VDPHL01, an extended-release oral minoxidil candidate for pattern hair loss.
VeraDermics (MANE) shares rose 12.44% in intraday trading following the release of positive clinical trial results for VDPHL01, an extended-release oral minoxidil candidate for pattern hair loss. The Phase 2 study, which included 28 women with mild-to-moderate pattern hair loss, demonstrated a mean…
AInvest Wire · 7d agoVeradermics shares jump 23% to record, up most since April
Veradermics shares surged 23% on Monday, reaching a record high and marking the largest single-day gain since April 2026. The stock has risen approximately 500% since its February 2026 initial public offering, driven by positive clinical results for its oral minoxidil formulation for male and…
AInvest Wire · 7d agoVeradermics gets upside 90-day catalyst watch at Cit
AInvest Wire · Sep 15, 2026Veradermics Inc: Citigroup raises target price to $160 from $135
Citigroup has raised its price target for Veradermics, Incorporated (NYSE: MANE) to $160 from $135, maintaining a positive outlook on the stock. This adjustment follows the company’s announcement of positive topline results from Part A of its Phase 2/3 trial for VDPHL01, an extended-release oral…
AInvest Wire · Jul 16, 2026ImportantVeradermics shares gain nearly 14% after oral hair loss drug shows positive mid-stage data in women
AInvest Wire · Jul 15, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.